Jackson Creek Investment Advisors’s Travere Therapeutics TVTX Stock Holding History

Jackson Creek Investment Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-42,121	Closed	-$1.08M	–	379
2022 Q1	$1.08M	Buy	42,121 +4,032	+11%	+$107K	0.4%	107
2021 Q4	$1.18M	Buy	+38,089	New	+$1.07M	0.42%	78
2021 Q2	–	Sell	-42,055	Closed	-$1.05M	–	356
2021 Q1	$1.05M	Sell	42,055 -1,250	-3%	-$34.5K	0.36%	142
2020 Q4	$1.18M	Sell	43,305 -73	-0.2%	-$1.7K	0.46%	48
2020 Q3	$801K	Buy	+43,378	New	+$843K	0.36%	121

Other funds holding TVTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Jackson Creek Investment Advisors's TVTX Position: Q2 2022 in Review

Jackson Creek Investment Advisors sold out of Travere Therapeutics (TVTX) in Q2 2022, closing a stake of 42,121 shares — an estimated $1.08M sold.

Jackson Creek Investment Advisors first reported a position in TVTX in Q3 2020 and held it in 5 quarters. The position peaked at $1.18M in Q4 2021. 171 funds tracked by Wall St. Rank hold TVTX as of Q2 2022.

Jackson Creek Investment Advisors reported no remaining Travere Therapeutics position as of Q2 2022 after selling out during the quarter.
Jackson Creek Investment Advisors sold 42,121 Travere Therapeutics shares in Q2 2022, an estimated $1.08M.
Jackson Creek Investment Advisors first reported a position in Travere Therapeutics in Q3 2020 and held it in 5 quarters.
Jackson Creek Investment Advisors's Travere Therapeutics position peaked at $1.18M in Q4 2021.
171 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2022.

Based on Jackson Creek Investment Advisors's 13F filing for Q2 2022, filed 4 Aug 2022.